BRL-26921

We report the results of two consecutive studies using intravenous bolus injections of streptokinase (SK) or acylated plasminogen… Expand

Thrombolytic therapy was used for 57 patients with acute and sub-acute lower limb arterial ischaemia. In the first 34 patients a… Expand

 

The role of thrombus-binding in the fibrinolytic response to the acylated streptokinase.plasminogen activator complex, BRL 26921… Expand

The main goal of therapeutic thrombolysis in acute myocardial infarction is early reperfusion of acutely obstructed coronary… Expand

BRL 26921 is a protected plasminogen-streptokinase complex with selective affinity for thrombus. When given intravenously within… Expand

The effects of BRL 26921, an active-site acylated streptokinase-plasminogen complex, on the fibrinolytic and coagulation systems… Expand

BRL 26921 is the p- anisoyl derivative of the primary streptokinase-human plasminogen complex in which the acyl group is… Expand

In view of current interest in the possibility of rapid, high-dose administration of thrombolytic agents by the intravenous route… Expand

Abstract The fibrinolytic and thrombolytic properties of BRL 26921, a p-anisoylated streptokinase-plasminogen complex, were… Expand